Moreover, since the United States Food and Drug Administration (FDA) approval of targeted inhibitors for FLT3, isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) gene mutations, predictive biomarkers are also now needed to select AML patients for targeted therapy [4,5,6]. The gene discussed is FLT3; the disease is acute myeloid leukemia.